These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36923472)

  • 21. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
    Mahan SD; Riching KM; Urh M; Daniels DL
    Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target protein localization and its impact on PROTAC-mediated degradation.
    Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
    Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
    Lospinoso Severini L; Bufalieri F; Infante P; Di Marcotullio L
    Front Cell Dev Biol; 2022; 10():854352. PubMed ID: 35242765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
    Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
    ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
    He S; Gao F; Ma J; Ma H; Dong G; Sheng C
    Angew Chem Int Ed Engl; 2021 Oct; 60(43):23299-23305. PubMed ID: 34240523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex.
    Lin W; Chen T
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):941-952. PubMed ID: 33860212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
    Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
    Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring PROTAC interactions in biochemical assays using Lumit immunoassays.
    Crummy EK; Caine EA; Mikheil D; Corona C; Riching KM; Hosfield C; Urh M
    Methods Enzymol; 2023; 681():81-113. PubMed ID: 36764765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PROTACs in gastrointestinal cancers.
    Chen Y; Yang Q; Xu J; Tang L; Zhang Y; Du F; Zhao Y; Wu X; Li M; Shen J; Ding R; Cao H; Li W; Li X; Chen M; Wu Z; Cho CH; Du Y; Wen Q; Xiao Z
    Mol Ther Oncolytics; 2022 Dec; 27():204-223. PubMed ID: 36420306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PROTACs to address the challenges facing small molecule inhibitors.
    Martín-Acosta P; Xiao X
    Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles.
    Chen J; Qiu M; Ma F; Yang L; Glass Z; Xu Q
    J Control Release; 2021 Feb; 330():1244-1249. PubMed ID: 33234362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.
    Yokoo H; Naganuma M; Oba M; Demizu Y
    Chem Biodivers; 2022 Nov; 19(11):e202200828. PubMed ID: 36124821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines.
    Zhai J; Li C; Sun B; Wang S; Cui Y; Gao Q; Sang F
    Bioorg Med Chem Lett; 2022 Dec; 78():129041. PubMed ID: 36332882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor.
    Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
    Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
    Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target and tissue selectivity of PROTAC degraders.
    Guenette RG; Yang SW; Min J; Pei B; Potts PR
    Chem Soc Rev; 2022 Jul; 51(14):5740-5756. PubMed ID: 35587208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.